Abstracts Archive - Page 665 of 2607 - ACR Meeting Abstracts

Abstract Number: 1974 • ACR Convergence 2022
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
Andreas Kerschbaumer¹, Victoria Konzett², Josef Smolen¹ and Daniel Aletaha³, ¹Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology / Department of Medicine III / Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Wien, Austria
Background/Purpose: The American College of Rheumatology (ACR) response definition was developed in 1995 by Felson et al. as a composite outcome and has been the…
Abstract Number: 1972 • ACR Convergence 2022
Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach
Lilla Tóth¹, Gergely Orsi², Krisztina Csókási³, Gábor Sütő⁴, Gábor Kumánovics⁵, Noémi Császár-Nagy⁶, Szabolcs Takács⁷, Eszter Szigedi⁸, Zsófia Nagy⁸, Zsolt Hodovány⁸, Lili Duzsik⁸, Zoltán Vidnyánszky⁹, József Kun¹⁰, Péter Urbán¹⁰, György Nagy¹¹ and Zsuzsanna Helyes¹², ¹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary, ²MTA-PTE Clinical Neuroscience MR Research Group, Eötvös Loránd Research Network (ELKH); Department of Neurology, Medical School, University of Pecs, Pécs, Hungary, ³Institute of Psychology, Faculty of Humanities and Social Sciences, University of Pécs, Pécs, Hungary, ⁴Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ⁵Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ⁶National University of Public Services; Psychosomatic Outpatient Clinics, Budapest, Hungary, ⁷Department of Psychology, Karoly Gaspar University, Budapest, Hungary, ⁸Psychosomatic Outpatient Clinics, Budapest, Hungary, ⁹Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ¹⁰Szentágothai Research Centre, Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, University of Pécs, Pécs, Hungary, ¹¹Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University; Department of Genetics, Cell and Immunobiology, Semmelweis University; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ¹²Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs; Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Pécs, Hungary
Background/Purpose: Despite the therapeutic advances of rheumatoid arthritis (RA), optimal disease control cannot be achieved in the difficult-to-treat (D2T) RA population, leading to the persistence…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 1976 • ACR Convergence 2022
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Amar Suwal¹, Biraj Shrestha², Ibiyemi Oke² and Anthony Donato², ¹Reading Hospital, Tower Health, Reading, PA, ²reading hospital- tower health, Reading, PA
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Karin Andersson¹, Eric Malmhäll-Bah², Nina Oparina¹, Tao Weiyang³, Malin Erlandsson¹, Venkataragavan Chandrasekaran², Aridaman Pandit³, Sofia Töyrä Silfverswärd⁴, Maria Bokarewa⁴ and Rille pullerits⁴, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Translational Immunology, University Medical Center, Utrecht, Netherlands, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…
Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Eric Malmhäll-Bah¹, Karin Andersson², Nina Oparina², Sofia Töyrä Silfverswärd³, Malin Erlandsson² and Maria Bokarewa³, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…
Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 1968 • ACR Convergence 2022
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Nora Petrovská², Petra Hánová¹, Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
Abstract Number: 1896 • ACR Convergence 2022
Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study
Juan-Pablo Zertuche¹, Gabriela Rabasa¹, Alice H. Lichtenstein², Nirupa R. Matthan², Michael Nevitt³, James Torner⁴, Cora E. Lewis⁵, Devyani Misra⁶ and David Felson¹, ¹Boston University, Boston, MA, ²Tufts University, Boston, MA, ³University of California at San Francisco, Orinda, CA, ⁴University of Iowa, Iowa City, IA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Beth Israel Deconess Medical Center, Boston, MA
Background/Purpose: Whole grains, particularly wheat, are an important source of dietary fiber in the US. By providing a fermentable source, whole grains can modify the…
Abstract Number: 1800 • ACR Convergence 2022
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Yue Yin¹, Yun Zhang¹, Hong Di¹, Xinxin Han¹ and Xuejun Zeng², ¹Peking Union Medical College Hospital, Beijing, China, ²Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: Gout is an inflammatory disease caused by the deposition of MSU crystals in joints and other parts. At present, little progress in the research…
Abstract Number: 1608 • ACR Convergence 2022
Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Huan Meng¹, Isaac Cheng², Byran P Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam², ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28)…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Lotte van Ouwerkerk¹, Sytske Anne Bergstra², Tjardo Maarseveen¹, Rachel Knevel¹, Tom Huizinga¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].